Effects of surgical septal myectomy on left ventricular wall thickness and diastolic filling

Pedro F Monteiro1, Steve R Ommen, Bernard J Gersh

  • 1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Insights

Surgical myectomy improves left ventricular (LV) structure and diastolic function in obstructive hypertrophic cardiomyopathy patients. This procedure leads to reduced LV wall thickness and enhanced LV filling, indicating long-term benefits.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Echocardiography

Background:

  • Obstructive hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening of the left ventricular (LV) walls.
  • Surgical myectomy is a treatment option for symptomatic obstructive HCM.
  • Understanding the long-term effects of myectomy on LV structure and function is crucial.

Purpose of the Study:

  • To evaluate the late effects of surgical myectomy on left ventricular (LV) structure and diastolic function in patients with obstructive hypertrophic cardiomyopathy.
  • To assess changes in LV dimensions, wall thickness, and diastolic filling patterns post-myectomy.

Main Methods:

  • Retrospective analysis of patients with obstructive hypertrophic cardiomyopathy who underwent surgical myectomy.
  • Inclusion of patients with echocardiographic studies performed before and at least 6 months after surgery.
  • Analysis of left ventricular cavity dimension, septal and posterior wall thicknesses, and Doppler flow variables.

Main Results:

  • Surgical myectomy resulted in a significant reduction in mean septal thickness (23.6 vs 19.5 mm, p <0.001) and LV posterior wall thickness (14.2 vs 12.4 mm, p <0.001).
  • Mitral inflow Doppler velocity curves showed improvement in LV diastolic filling, evidenced by a decrease in mitral E velocity (0.95 to 0.87 m/s, p = 0.008).

Conclusions:

  • Surgical myectomy leads to favorable left ventricular (LV) remodeling, including reduced wall thickness.
  • The procedure improves LV diastolic filling, contributing to the observed long-term clinical benefits in obstructive hypertrophic cardiomyopathy patients.

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...